ARANDA ® Levofloxacin

ARANDA ® is a drug based on Levofloxacin hemihydrate

THERAPEUTIC GROUP: Antimicrobials - antibiotics for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions ARANDA ® Levofloxacin

ARANDA ®, as a third-generation Quinolone-based drug, is particularly effective, therefore indicated, in the treatment of respiratory infections, skin and appendages supported by bacteria sensitive to Levofloxacin.

Mechanism of action ARANDA ® Levofloxacin

Levofloxacin, the active ingredient of ARANDA ®, is an antibiotic belonging to the third generation Fluoroquinolones family which is particularly effective against intracellular microorganisms, Streptococci, Enterococci and Mycobacteria.

Its bacteriostatic activity, a concentration dependent and endowed with a prolonged post-antibiotic effect, is due to the ability to bind and form inactive complexes with enzymes involved in DNA duplication mechanisms such as gyrases and topoisomerases.

The inhibition of these replication mechanisms, by controlling the bacterial proliferation rate, prevents the colonization of mucous membranes and tissues, guaranteeing a regression of symptoms in just a few days of treatment.

However, in some cases the antibiotic activity may be compromised by the onset of resistance mechanisms, such as the expression of efflux pumps rather than the expression of inactivating enzymes or modifications of the biological target responsible for resistance to drug therapy.

The inadequate use of antibiotics is the main cause of this condition.

Studies carried out and clinical efficacy

LEVOFLOXACINE IN THE TREATMENT OF INFECTION BY H.PYLORI

Work that tests the effectiveness of the antibiotic regimen consisting of Levofloxacin + Rifamycin in the eradication of H.Pylori, observing an efficacy similar to the triple or quadruple therapy commonly used in the clinical setting.

MIASTENIC CRISIS BY LEVOFLOXACINA

Case report that reports the appearance of myasthenic crisis in a patient undergoing antibiotic therapy with Levofloxacin. Such emergencies emphasize the importance of medical supervision even during antibiotic therapy.

THE EFFECTIVENESS OF LEVOFLOXACINE IN THE TREATMENT OF INFECTIONS OF THE RESPIRATORY PATHWAYS

Isolated study demonstrating the efficacy of Levofloxacin, in combination also with Clarithromycin, in determining a regression of the symptomatology in a patient affected by Mycobacterium Kyorinense, responsible for severe pulmonary pictures.

Method of use and dosage

ARANDA ®

Levofloxacin 250 - 500 mg coated tablets.

The dosages, generally between 250 - 1000 mg of Levofloxacin daily and divided into two administrations, should be defined by your doctor based on the patient's physiopathological characteristics, the severity of his clinical picture and the therapeutic goals to be achieved.

In order to optimize the therapeutic success, avoiding unpleasant pathologies of pathology, it is recommended to prolong the therapy for at least 48 hours from the disappearance of the symptoms.

Warnings ARANDA ® Levofloxacin

The use of ARANDA ® should be preceded by a careful medical examination in order to assess the prescriptive appropriateness and the possible presence of contraindications to the use of Fluoroquinolones.

Particular caution should be reserved for patients suffering from renal pathologies, given the reduced ability to eliminate the drug, for patients suffering from glucose 6 phosphate dehydrogenase enzyme deficiency, due to the increased incidence of hemolytic episodes, and to developing patients, known the documented risk of arthropathy and tendinitis.

The patient receiving ARANDA ® should also avoid direct exposure to sunlight, given the drug-induced photosensitivity and the potential appearance of erythema and skin rash.

Prolonged and inadequate use of this antibiotic could result in the selection of multiresistant microbial strains such as Clostridium difficile, responsible for serious pathological conditions such as pseudomembranous colitis.

PREGNANCY AND BREASTFEEDING

The aforementioned contraindications also extend to pregnancy and the subsequent breastfeeding period, given Levofloxacin's ability to cross both the placental barrier and the breast filter, exposing itself to the fetus and infant in pharmacologically active concentrations.

Interactions

Patients on ARANDA ® therapy should pay particular attention to the simultaneous intake of:

Foods, supplements and drugs containing divalent metals, given the ability to form chelating complexes, responsible for reducing the therapeutic efficacy of the antibiotic;
Tiazanidine, methotrexate, theophylline, xanthine and phenytoin due to the altered tubular secretion induced by Fluoroquinolone and the consequent strengthening of biological and collateral effects;
Oral anticoagulants, due to the increased anticoagulant activity induced by the antibiotic.

Contraindications ARANDA ® Levofloxacin

ARANDA ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, in patients who are developing, in patients with severe renal and epileptic diseases.

Undesirable effects - Side effects

The use of ARANDA ®, especially when prolonged over time, could cause the appearance of nausea, diarrhea, vomiting, abdominal pain and in severe cases pseudomembranous colitis, hypertransaminasemia and impaired renal function, headache, irritability, convulsions and epileptogenic risk, and only rarely tendinitis and arthralgias, especially during growth phases.